MedCity News January 8, 2025
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO market’s return to normal levels.
A case can be made that metabolic medicine was the theme of the life sciences industry in 2024. Insatiable market demand fueled rocketing revenue growth for Novo Nordisk, which makes Wegovy, and Eli Lilly, maker of Zepbound. This commercial success is paving the way for metabolic drug research more broadly, as would-be contenders aim to develop new and better products for weight loss.
While this space has become active and crowded, not so long ago, obesity drugs were a research desert. Omar...
Today's Sponsors
Today's Sponsor